108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
木村病：53 例回顾性分析及 3 例美泊利单抗治疗有效病例
Authors Zhu W, Zhang L, Zhang J, Wang W, Xiang Y, He D, Shi J, Liang Y, Shi Y, Ning X, Jin M, Ye L
Received 7 May 2025
Accepted for publication 26 September 2025
Published 4 October 2025 Volume 2025:18 Pages 13773—13785
DOI https://doi.org/10.2147/JIR.S538560
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Ning Quan
Wenjiao Zhu,1,* Lei Zhang,2,* Jing Zhang,3,* Wei Wang,4 Ye Xiang,1 Dingxian He,5 Jing Shi,1 Yiran Liang,1 Yuanping Shi,6 Xianhui Ning,7 Meiling Jin,1 Ling Ye1
1Department of Allergy, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China; 2Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China; 3Department of Pathology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People’s Republic of China; 4Department of Neurosurgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People’s Republic of China; 5Department of Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, People’s Republic of China; 6Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, 100044, People’s Republic of China; 7Department of Otolaryngology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Meiling Jin, Email mljin118@163.com Ling Ye, Email ye.ling@zs-hospital.sh.cn
Background: Kimura disease (KD) is a rare, chronic lymphoproliferative disorder, which is believed to be driven by a Th2 immune response, though its exact pathogenesis remains unclear. Despite various treatment approaches, no standardized therapy has been established. This study investigated the clinical features of 53 KD patients and evaluated the therapeutic potential of mepolizumab in three cases.
Methods: A retrospective age-stratified analysis was performed on 53 patients diagnosed with KD at two tertiary medical centers in China, covering the period from January 2014 to December 2024. We also provided an in-depth case series of three patients who received mepolizumab treatment.
Results: This study included 53 KD patients, predominantly male (88.7%) with a mean age of 41 years. The median time from symptom onset to diagnosis was 24 months, and the median lesion diameter was 3.0 cm. Pruritus was present in 52.8% of patients, with frequency increasing with age (P=0.015). Coexisting conditions included IgG4-related disease (11.3%), asthma (9.4%), and thrombotic events (9.4%). Lesions were bilateral in 66.0% and primarily located in the head and neck region (83.0%). Average eosinophil count was 2.09 × 109/L, and mean serum IgE level was 1069 IU/mL. Surgical excision (62.3%) is the most common initial treatment approach, followed by corticosteroids (15.1%). The overall recurrence rate is 60.4%. In the case series, three patients treated with different doses of mepolizumab showed favorable responses, including lymph nodes shrink, symptom control and eosinophil reduction.
Conclusion: This study provided a comprehensive summary and age-stratified analysis of the clinical characteristics of KD, providing valuable insights into its pathophysiology and potential overlapping mechanisms. Additionally, the study presents clinical cases of three patients treated with mepolizumab, highlighting its potential as a promising therapeutic option for the management of KD.
Keywords: Kimura disease, eosinophilia, type 2 inflammation, mepolizumab
1Department of Allergy, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China; 2Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China; 3Department of Pathology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People’s Republic of China; 4Department of Neurosurgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People’s Republic of China; 5Department of Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, People’s Republic of China; 6Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, 100044, People’s Republic of China; 7Department of Otolaryngology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Meiling Jin, Email mljin118@163.com Ling Ye, Email ye.ling@zs-hospital.sh.cn
Background: Kimura disease (KD) is a rare, chronic lymphoproliferative disorder, which is believed to be driven by a Th2 immune response, though its exact pathogenesis remains unclear. Despite various treatment approaches, no standardized therapy has been established. This study investigated the clinical features of 53 KD patients and evaluated the therapeutic potential of mepolizumab in three cases.
Methods: A retrospective age-stratified analysis was performed on 53 patients diagnosed with KD at two tertiary medical centers in China, covering the period from January 2014 to December 2024. We also provided an in-depth case series of three patients who received mepolizumab treatment.
Results: This study included 53 KD patients, predominantly male (88.7%) with a mean age of 41 years. The median time from symptom onset to diagnosis was 24 months, and the median lesion diameter was 3.0 cm. Pruritus was present in 52.8% of patients, with frequency increasing with age (P=0.015). Coexisting conditions included IgG4-related disease (11.3%), asthma (9.4%), and thrombotic events (9.4%). Lesions were bilateral in 66.0% and primarily located in the head and neck region (83.0%). Average eosinophil count was 2.09 × 109/L, and mean serum IgE level was 1069 IU/mL. Surgical excision (62.3%) is the most common initial treatment approach, followed by corticosteroids (15.1%). The overall recurrence rate is 60.4%. In the case series, three patients treated with different doses of mepolizumab showed favorable responses, including lymph nodes shrink, symptom control and eosinophil reduction.
Conclusion: This study provided a comprehensive summary and age-stratified analysis of the clinical characteristics of KD, providing valuable insights into its pathophysiology and potential overlapping mechanisms. Additionally, the study presents clinical cases of three patients treated with mepolizumab, highlighting its potential as a promising therapeutic option for the management of KD.
Keywords: Kimura disease, eosinophilia, type 2 inflammation, mepolizumab